Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference

Kadmon Holdings, Inc. (NYSE:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at the 28th Annual Piper Jaffray Healthcare Conference on Wednesday, November 30, 2016 at 8:00 a.m. ET.

A live audio webcast of the presentation may be accessed on the Investors section of the Kadmon website at www.kadmon.com. A replay of the webcast will be available for 90 days.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology and genetic diseases.

Safe Harbor Statement

This press release contains forward-looking statements. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's Quarterly Report on Form 10-Q filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC on November 9, 2016. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161128005200/en/

Kadmon Holdings, Inc.Ellen Tremaine, 646-490-2989Investor Relationsellen.tremaine@kadmon.comorMaeve Conneighton, 212-600-1902maeve@argotpartners.com

Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2024 to Apr 2024